Newsoara Biopharma Co., Ltd.
恒翼生物
- Headquarters
- Shanghai, China
Clinical-stage assets
| Asset | Stage at source date | Indication | Source date |
|---|---|---|---|
| Prifemilast / HY1999 / HPP737 | Phase 3 in psoriasis; Phase 2/2b in IBD | Not disclosed | 2026-06-18 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-06-18 | cAMPfield Therapeutics, Inc. | Prifemilast / HY1999 / HPP737 | Not disclosed | Not disclosed | Not disclosed | Phase 3 in psoriasis; Phase 2/2b in IBD |